desk
Share
News Topical, Digital Desk : Pharma company Lupin announced after the stock market closed on Friday that the US drug regulator, the US FDA, inspected the company's Goa manufacturing facility from November 10 to November 21, 2025. The inspection concluded with a Form-483, in which seven observations were issued. The company stated that it will submit a resolution to these observations within the stipulated timeframe and is committed to ensuring compliance with CGMP standards at all its plants.
Lupin is a Mumbai-headquartered global pharmaceutical company with products available in over 100 markets. The company specializes in manufacturing branded and generic formulations, complex generics, biotechnology products, and APIs. According to the company, Lupin's consolidated net profit increased by 73.33 percent to ₹1,477.92 crore for the quarter ended September 2025, compared to ₹852.63 crore in the same quarter last year.
Share Performance On Friday, the company's shares closed at ₹2,031, down 0.0098 percent. In the past year, the company's shares have declined by 1.95 percent.
Read More: IPO: 3 companies to list next week, one expected to offer 47% returns, read GMP's indications
--Advertisement--
